Close Menu

NEW YORK — Yourgene Health said on Friday that it has received approval to sell its Elucigene DPYD chemotoxicity diagnostic assay in Australia.

The genotyping test, which was launched last year, is designed to identify cancer patients with dihydropyrimidine dehydrogenase deficiency, which can result in life-threatening side effects when the patients are treated with the chemotherapeutic agent 5-fluorouracil. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.